Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Pfizer’s research partnership with Sangamo Therapeutics produced a hemophilia A gene therapy that reached FDA discussions about a regulatory submission. That’s as far as the alliance will go.

Pfizer Inc. abruptly ended a key hemophilia A gene therapy collaboration with Sangamo Therapeutics Inc., sending the East Bay biotech company's stock sharply lower as its partnership options thinned.

Sangamo chief executive Sandy Macrae has said the company is "surprised and extremely disappointed" by Pfizer's decision to hand back rights to its experimental gene therapy for haemophilia A ...

Pfizer has abandoned development of a hemophilia A gene therapy it licensed from Sangamo Therapeutics, a move that could imperil Sangamo’s future. It’s a sudden turnabout for Pfizer ...

(Reuters) -Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development agreement, sending its shares down nearly 64% in extended trade.

Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future ...

Pfizer and Sangamo are hoping for a faster trajectory with their experimental treatment. The partners' one-shot giroctocogene fitelparvovec therapy has cleared a phase 3 trial, showing it was ...

Truist analyst Nicole Germino keeps a BUy rating on Sangamo (SGMO) after the company announced the hemophilia A gene therapy partnership was terminated with partner Pfizer (PFE), which is expected ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) regained the development and commercialization rights to giroctocogene fitelparvovec, an investigational gene therapy product candidate for moderately severe ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...